These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 31434709

  • 1. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
    Polesso F, Sarker M, Weinberg AD, Murray SE, Moran AE.
    J Immunol; 2019 Oct 01; 203(7):2011-2019. PubMed ID: 31434709
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
    Kitamura N, Murata S, Ueki T, Mekata E, Reilly RT, Jaffee EM, Tani T.
    Int J Cancer; 2009 Aug 01; 125(3):630-8. PubMed ID: 19455675
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.
    Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson HL, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, Smothers J, Srinivasan R, Paul EM, Yanamandra N, Hwu P.
    Clin Cancer Res; 2019 Nov 01; 25(21):6406-6416. PubMed ID: 31371342
    [Abstract] [Full Text] [Related]

  • 6. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
    Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL.
    J Immunol; 2017 Aug 01; 199(3):974-981. PubMed ID: 28646041
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD.
    J Immunol; 2007 Dec 01; 179(11):7244-53. PubMed ID: 18025166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4-Targeted Immunotherapy.
    Emerson DA, Rolig AS, Redmond WL.
    Cancer Immunol Res; 2021 Apr 01; 9(4):430-440. PubMed ID: 33593794
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. New insights on OX40 in the control of T cell immunity and immune tolerance in vivo.
    Xiao X, Gong W, Demirci G, Liu W, Spoerl S, Chu X, Bishop DK, Turka LA, Li XC.
    J Immunol; 2012 Jan 15; 188(2):892-901. PubMed ID: 22147766
    [Abstract] [Full Text] [Related]

  • 14. Inhibiting OX40 Restores Regulatory T-Cell Function and Suppresses Inflammation in Pulmonary Sarcoidosis.
    Kumari R, Chakraborty S, Jain R, Mitra S, Mohan A, Guleria R, Pandey S, Chaudhury U, Mitra DK.
    Chest; 2021 Sep 15; 160(3):969-982. PubMed ID: 33901497
    [Abstract] [Full Text] [Related]

  • 15. Regulatory T cells: a potential target in cancer immunotherapy.
    Shitara K, Nishikawa H.
    Ann N Y Acad Sci; 2018 Apr 15; 1417(1):104-115. PubMed ID: 29566262
    [Abstract] [Full Text] [Related]

  • 16. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right.
    Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD.
    J Immunol; 2009 Oct 15; 183(8):4853-7. PubMed ID: 19786544
    [Abstract] [Full Text] [Related]

  • 17. OX40 costimulation turns off Foxp3+ Tregs.
    Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC.
    Blood; 2007 Oct 01; 110(7):2501-10. PubMed ID: 17575071
    [Abstract] [Full Text] [Related]

  • 18. Science gone translational: the OX40 agonist story.
    Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD.
    Immunol Rev; 2011 Nov 01; 244(1):218-31. PubMed ID: 22017441
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN, Kasiewicz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL.
    Proc Natl Acad Sci U S A; 2016 Jan 19; 113(3):E319-27. PubMed ID: 26729864
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.